Engineered Endothelial Cells for Implant Vascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biocompatible implants struggle to integrate effectively into host tissues due to slow endothelial cell infiltration and blood vessel formation, with previous methods often failing to produce functional blood vessels within three-dimensional scaffolds in vitro, especially without fibroblast co-culture.
Innovation Solution
Engineered endothelial cells expressing the adenovirus E4ORF1 protein are cultured within biocompatible scaffolds composed of extracellular matrix molecules, collagen, fibrin, or decellularized animal tissue, enabling the formation of blood vessels with open lumens in vitro, even in the absence of fibroblasts, and these vessels can protrude beyond the scaffold boundaries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional methods using collagen gels or Matrigel are used to induce blood vessel formation, then endothelial cells can be cultured, but functional blood vessels with patent lumens do not form without fibroblast co-culture
Solution Approach 1:
The patent extracts and removes the requirement for fibroblast co-culture from the blood vessel formation system. By using engineered endothelial cells that autonomously form functional blood vessels with patent lumens in collagen gels or Matrigel without needing fibroblasts, the system eliminates the complexity of maintaining multiple cell types while achieving reliable vascularization.
Solution Approach 2:
The engineered endothelial cells are designed to self-organize and self-assemble into functional blood vessels autonomously. These cells possess inherent capabilities to form patent lumens and mature vascular structures without requiring external support from fibroblast-derived matrix proteins, enabling the system to serve itself.
2Reliability
If fibroblast co-culture is used to support endothelial cell lumen formation, then blood vessels with patent lumens can form, but the system complexity and manufacturing difficulty increase
Solution Approach 1:
The invention extracts fibroblasts from the co-culture system, demonstrating that engineered endothelial cells alone can form patent lumens and functional blood vessels. This removal of fibroblasts dramatically simplifies the manufacturing process by eliminating the need to culture, maintain, and coordinate multiple cell types during implant production.
Solution Approach 2:
The patent changes the biological parameters of the endothelial cells through genetic engineering,赋予 them enhanced capabilities to form stable lumens and mature vascular structures autonomously. This parameter change in cell behavior allows the system to achieve reliable lumen formation without the complicating factor of fibroblast co-culture.
3Reliability
If endothelial cells are cultured in three-dimensional scaffolds in vitro, then vascular structures can form, but the process takes extended time and requires precise control conditions
Solution Approach 1:
The engineered endothelial cells are pre-engineered with enhanced vascularization capabilities before implantation. This preliminary genetic modification enables them to rapidly form functional blood vessels upon implantation, significantly reducing the in vivo vascularization time compared to conventional cells that would require extended culture periods to achieve similar results.
4Stability of the object's composition
If conventional endothelial cells are used in implants, then the implant structure can be maintained, but integration into host vasculature is slow and inefficient
Solution Approach 1:
The patent changes key biological parameters of the endothelial cells through genetic engineering, enhancing their ability to proliferate, migrate, and form functional connections with host vasculature. These parameter changes enable rapid integration while maintaining implant structural stability, as the engineered cells preserve normal endothelial functions while gaining enhanced regenerative capabilities.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The present invention involves implants suitable for surgical implantation into subjects. In some embodiments the implants comprise a biocompatible scaffold material and blood vessels containing engineered endothelial cells - such as E4ORF1+ engineered endothelial cells or engineered endothelial cells that express certain marker molecules. The present invention provides implants, methods for preparing such implants, and methods of treatment utilizing such implants.